



## MannKind to Present at 2024 UBS Healthcare Conference

11/05/24

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference in Rancho Palos Verdes, Calif.

The fireside chat will take place on Tuesday, November 12, at 10:15 a.m. Pacific Time. A link to the live audio webcast of the session will be available on MannKind Corporation's website at: <https://investors.mannkindcorp.com/events-and-presentations>. A recorded version will also be available on the website for approximately 30 days following the conference.

### About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit [mannkindcorp.com](http://mannkindcorp.com) to learn more, and follow us on [LinkedIn](#), [Facebook](#), [X](#) or [Instagram](#).

This press release was published by a CLEAR® Verified individual.

For MannKind: □  
Investor Relations  
Ana Kapor  
(818) 661-5000  
Email: [ir@mnkd.com](mailto:ir@mnkd.com)

Media Relations  
Christie Iacangelo  
(818) 292-3500  
Email: [media@mnkd.com](mailto:media@mnkd.com)



Source: MannKind